A fully automated, AI-powered solution for assessment of solid tumors

There is a growing need to augment traditional human-measured lengths such as RECIST for treatment response assessment in oncology.

Brainomix’s Cancer solution has been trained to characterize and quantify solid-tumors using thousands of cases from leading academic institutions, unlocking objective measurement of tumor lengths, and other biomarkers such as tumor volume.

Desktop_e-Cancer_Prespective_Horizontal

AI-powered biomarkers from Brainomix's Cancer solution are available now for use in clinical trials, and can support:

Efficacy detection, as an adjunct to traditional human-derived measures such as RECIST

Blinded Independent Central Review (BICR) with AI-powered objectivity and standardization

Objective assessment and comparison of early-stage treatments

Reduced sample sizes and faster trial execution

Contact Us Today

Speak with us to learn how to integrate our oncology biomarkers into your clinical trials and clinical research.

Hear from our valued partners and collaborators

Our Partners

Leave Your Legacy Portuguese Logo
Stryker
OSIC Logo
Boehringer Ingelheim Logo
Nvidia Logo
NCIMI Logo
GE Healthcare
Wallaby Logo
TCPDS MEMBER BLACK